Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer
eLife · 04.06.2025 · 14
DOI: 10.7554/elife.103953 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 04.06.2025. Verfasst von Yijia Hua und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Drug Resistance, Neoplasm, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, High-level Innovation Team of Nanjing Medical University Program, The Collaborative Innovation Center for Tumor Individualization Program.
Abstract (Originalsprache)
Trastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies. Here, we integrated metabolomics, transcriptomics, and epigenomics data of trastuzumab-sensitive and primary-resistant HER2-positive breast cancer to identify metabolic alterations. Aberrant cysteine metabolism was discovered in trastuzumab primary-resistant breast cancer at both circulating and intracellular levels. The inhibition of SLC7A11 and cysteine starvation could synergize with trastuzumab to induce ferroptosis. Mechanistically, increased H3K4me3 and decreased DNA methylation enhanced SLC7A11 transcription and cystine uptake in trastuzumab-resistant breast cancer. The regulation of epigenetic modifications modulated cysteine metabolism and ferroptosis sensitivity. These results revealed an innovative approach for overcoming trastuzumab resistance by targeting specific amino acid metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
- Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany.
- Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Yijia Hua, Ningjun Duan, Yongmei Yin
Förderung
- National Natural Science Foundation of China
- High-level Innovation Team of Nanjing Medical University Program
- The Collaborative Innovation Center for Tumor Individualization Program
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Hua, Y., Duan, N., Sun, C., Yang, F., Tian, M., Sun, Y., Zhao, S., Gong, J., Liu, Q., Huang, X., Liang, Y., Fu, Z., Li, W., & Yin, Y. (2025). Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer. eLife, 14. https://doi.org/10.7554/elife.103953
Vancouver
Hua Y, Duan N, Sun C, Yang F, Tian M, Sun Y, et al. Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer. eLife. 2025;14. doi:10.7554/elife.103953
BibTeX
@article{Hua2025,
author = {Hua, Yijia and Duan, Ningjun and Sun, Chunxiao and Yang, Fan and Tian, Min and Sun, Yanting and Zhao, Shuhan and Gong, Jue and Liu, Qian and Huang, Xiang and Liang, Yan and Fu, Ziyi and Li, Wei and Yin, Yongmei},
title = {Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer},
journal = {eLife},
year = {2025},
volume = {14},
doi = {10.7554/elife.103953}
}
EUVIMED